GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

r-glucagon

Company
Sanofi
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for r-glucagon and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06725693

    Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

    Tianjin Medical University 500 participants Est. completion 2027-11-01 3 sites
    Other conditions: GLP1-R-related Disease, Tumor, Insulinoma, Positron Emission Tomography
    View official trial listing →
  • Recruiting NCT NCT06939088

    Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

    Not yet reported Anders Fink-Jensen, MD, DMSci 108 participants Est. completion 2028-12-31 2 sites
    Alcohol use disorder Other conditions: Alcohol Abuse/Dependence, Alcoholism, Schizophrenia Disorders, Schizophrenia and Disorders With Psychotic Features, Schizophrenia and Schizophrenia Spectrum Psychosis, Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02232971

    Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes

    Not yet reported Hvidovre University Hospital 8 participants Est. completion 2015-07 1 site
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT02625636

    A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

    Not yet reported Sanofi 20 participants Est. completion 2016-02 1 site
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Withdrawn NCT NCT02635243

    A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia

    Not yet reported Sanofi Est. completion 2016-11
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT04053712

    Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes

    Not yet reported Steno Diabetes Center Copenhagen 13 participants Est. completion 2021-03-19 1 site
    Other conditions: Type 1 Diabetes, Hypoglycemia
    View official trial listing →
  • Completed NCT NCT04883346

    Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

    Not yet reported Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 34 participants Est. completion 2024-04-30 1 site
    Other conditions: Obesity, Status Post Sleeve Gastrectomy
    View official trial listing →
  • Completed NCT NCT04949867

    Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes

    Not yet reported Steno Diabetes Center Copenhagen 11 participants Est. completion 2022-04-26 2 sites
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Status unknown NCT NCT05389813

    Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia

    Not yet reported, Not yet reported An-Najah National University 150 participants Est. completion 2024-05-01 1 site
    Other conditions: Anesthesia
    View official trial listing →
  • Active, not recruiting NCT NCT05756764

    Anti-obesity Pharmacotherapy and Inflammation

    Louisiana State University Health Sciences Center in New Orleans 30 participants Est. completion 2026-02-20 2 sites
    Other conditions: Obesity
    View official trial listing →
  • Withdrawn NCT NCT06126354

    Dexamethasone/Pancreatic Clamp P&F

    Not yet reported Columbia University Est. completion 2026-03-31 1 site
    Other conditions: Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT06558422

    Human Models of Selective Insulin Resistance: Pancreatic Clamp

    Not yet reported Columbia University 36 participants Est. completion 2029-02-28 1 site
    MASLD Other conditions: Insulin Resistance, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.